GB0910032D0 - Use of serum composition to reduce the levels of TNF and/or VEGF in mammals - Google Patents
Use of serum composition to reduce the levels of TNF and/or VEGF in mammalsInfo
- Publication number
- GB0910032D0 GB0910032D0 GBGB0910032.2A GB0910032A GB0910032D0 GB 0910032 D0 GB0910032 D0 GB 0910032D0 GB 0910032 A GB0910032 A GB 0910032A GB 0910032 D0 GB0910032 D0 GB 0910032D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- vegf
- tnf
- mammals
- levels
- reduce
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0910032.2A GB0910032D0 (en) | 2009-06-11 | 2009-06-11 | Use of serum composition to reduce the levels of TNF and/or VEGF in mammals |
PCT/GB2010/050977 WO2010142997A1 (en) | 2009-06-11 | 2010-06-10 | Use of a serum composition to reduce the levels of tnf and/or vegf in mammals |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0910032.2A GB0910032D0 (en) | 2009-06-11 | 2009-06-11 | Use of serum composition to reduce the levels of TNF and/or VEGF in mammals |
Publications (1)
Publication Number | Publication Date |
---|---|
GB0910032D0 true GB0910032D0 (en) | 2009-07-22 |
Family
ID=40937224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0910032.2A Ceased GB0910032D0 (en) | 2009-06-11 | 2009-06-11 | Use of serum composition to reduce the levels of TNF and/or VEGF in mammals |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0910032D0 (en) |
WO (1) | WO2010142997A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2781742A1 (en) | 2013-01-17 | 2014-09-24 | Danfoss A/S | Shape memory alloy actuator for valve for refrigeration system |
WO2015036986A2 (en) * | 2013-09-16 | 2015-03-19 | Prendergast Patrick T | Wound fluid elevated protease enzyme inhibition through camelid blood products. |
EP3156746B1 (en) | 2015-10-14 | 2020-12-30 | Danfoss A/S | Expansion valve and vapour compression system |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2473754C (en) * | 2002-01-28 | 2012-04-10 | Aimsco Limited | Treatment of ms with goat serum |
EP1732648B1 (en) * | 2004-04-05 | 2009-12-09 | Aimsco Limited | Treatment of diseases |
WO2006021814A2 (en) * | 2004-07-08 | 2006-03-02 | Aimsco Limited | Medicament |
-
2009
- 2009-06-11 GB GBGB0910032.2A patent/GB0910032D0/en not_active Ceased
-
2010
- 2010-06-10 WO PCT/GB2010/050977 patent/WO2010142997A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2010142997A1 (en) | 2010-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267138A (en) | Improved cell composition and methods of making the same | |
BRPI1006441A2 (en) | composite structure with one surface and overmolded composite structure | |
IL219209A0 (en) | Il-17 family cytokine compositions and uses | |
EP2432462A4 (en) | Endoxifen methods and compositions in the treatment of mammalian diseases | |
PL2528610T3 (en) | Probiotic composition for use in the treatment of bowel inflammation | |
PL2516497T3 (en) | Composite materials comprising aggregate and an elastomeric composition | |
IL217389A0 (en) | Methods and compositions for the recombinant biosynthesis of n-alkanes | |
EP2407508A4 (en) | Resin composition and multilayered structure using the same | |
EP2554590A4 (en) | Resin composition and multilayered structure using same | |
EP2511333A4 (en) | Rubber composition and uses thereof | |
GB2483379B (en) | Solid cosmetic composition with structurant and electrolyte solution | |
EP2275481A4 (en) | Resin composition and multilayer structure using same | |
EP2491116A4 (en) | Cell-based anti-cancer compositions and methods of making and using the same | |
EP2282648A4 (en) | Prebiotic composition and methods of making and using the same | |
GB201005315D0 (en) | Seperation and quantitation of the C3-epimer of 250HD3 in serum using UPLC/MS/MS | |
EP2415837A4 (en) | Resin composition and multilayered structure | |
ZA201403592B (en) | Composition for use in the promotion of magnesium absorption and/or magnesium retention | |
GB0910032D0 (en) | Use of serum composition to reduce the levels of TNF and/or VEGF in mammals | |
PL2624859T3 (en) | Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy | |
GB201004004D0 (en) | Improvements in and relating to the consideration of evidence | |
EP2343199A4 (en) | Rubber composite and rubber composition | |
GB2456130B (en) | Improvements in and relating to the preparation of specimens | |
PT2155161T (en) | Stable liquid composition of chondroitinsulfate and glucosamine | |
PL2291657T3 (en) | Levels of blys/april heterotrimers in serum and use in diagnostic methods | |
GB0720400D0 (en) | Improvements in or relating to the preparation of beverages |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |